[Carbamazepine-associated pseudolymphoma].
Muñoz-Cerón
J F
JF
Nariño-González
D
D
Uribe-Granja
M
M
D000293:Adolescent; D000927:Anticonvulsants / Q000009:adverse effects* / Q000493:pharmacokinetics; D001711:Biotransformation; D002220:Carbamazepine / Q000009:adverse effects* / Q000031:analogs & derivatives / Q000378:metabolism / Q000493:pharmacokinetics; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D003937:Diagnosis, Differential; D003951:Diagnostic Errors; D004851:Epoxide Hydrolases / Q000172:deficiency; D005260:Female; D006801:Humans; D007377:Interleukin-3 / Q000378:metabolism; D015848:Interleukin-5 / Q000378:metabolism; D008223:Lymphoma / Q000175:diagnosis; D008954:Models, Biological; D019310:Pseudolymphoma / Q000139:chemically induced* / Q000175:diagnosis; D018746:Systemic Inflammatory Response Syndrome / Q000175:diagnosis; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000378:metabolism
D000927:Anticonvulsants; D007377:Interleukin-3; D015848:Interleukin-5; D002220:Carbamazepine; D004851:Epoxide Hydrolases; C012227:carbamazepine epoxide